Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins

Bayer 41-4109 is heteroarylpyrimidine (HAP) which has been identified as potent of HBV capsid assembly inhibitor. The present study was to study effect of Bayer 41-4109 treatment on the intracellular localization of EGFP-Core fusion proteins into HepG2 cells. Three recombinant plasmids of pEGFP-Core...

Full description

Bibliographic Details
Main Authors: Aris Haryanto, Nastiti Wijayanti, Michael Kann
Format: Article
Language:English
Published: Universitas Gadjah Mada, Yogyakarta 2007-12-01
Series:Indonesian Journal of Biotechnology
Online Access:https://jurnal.ugm.ac.id/ijbiotech/article/view/7775
_version_ 1831766966432432128
author Aris Haryanto
Nastiti Wijayanti
Michael Kann
author_facet Aris Haryanto
Nastiti Wijayanti
Michael Kann
author_sort Aris Haryanto
collection DOAJ
description Bayer 41-4109 is heteroarylpyrimidine (HAP) which has been identified as potent of HBV capsid assembly inhibitor. The present study was to study effect of Bayer 41-4109 treatment on the intracellular localization of EGFP-Core fusion proteins into HepG2 cells. Three recombinant plasmids of pEGFP-Core with single, double and triple NLS of HBV core (EGFP-Core 1C, 2C and 3C ) and two recombinant plasmids with single and triple NLS of SV-40 (EGFP-Core 1 and 3 SV-40) were used in this work. After transient transfected into HepG2 cells and treated with Bayer 41-4109, the intracellular localization of expressed fusion proteins from all plasmid constructions were determined and quantified under confocal laser microscope. Results shown that Bayer 41-4109 treatment in HepG2 cells inhibited the nuclear localization of EGFP-Core with single of triple HBV core NLS. As well as the constructions of expressed fusion protein with single and triple SV-40 NLS (EGFP-Core 1 and 3 SV-40 NLS) showed decreasing the nuclear localization after treated with Bayer 41-4109, even not as strong as EGFP-Core 1C and 3C NLS. Bayer 41-4109 has been identified as a potent inhibitors of HBV replication which has multiple effects on HBV capsid assembly. It may inhibit virus replication by inducing assembly inappropriately and by misdirecting assembly decreasing the stability of normal capsids. Keywords: HBV capsid, Bayer 41-4109, EGFP-Core fusion protein, HepG2 cell
first_indexed 2024-12-22T06:33:55Z
format Article
id doaj.art-61670fc51a3f4d5190b1db5594df365f
institution Directory Open Access Journal
issn 0853-8654
2089-2241
language English
last_indexed 2024-12-22T06:33:55Z
publishDate 2007-12-01
publisher Universitas Gadjah Mada, Yogyakarta
record_format Article
series Indonesian Journal of Biotechnology
spelling doaj.art-61670fc51a3f4d5190b1db5594df365f2022-12-21T18:35:39ZengUniversitas Gadjah Mada, YogyakartaIndonesian Journal of Biotechnology0853-86542089-22412007-12-0112210.22146/ijbiotech.77756502Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion ProteinsAris HaryantoNastiti WijayantiMichael KannBayer 41-4109 is heteroarylpyrimidine (HAP) which has been identified as potent of HBV capsid assembly inhibitor. The present study was to study effect of Bayer 41-4109 treatment on the intracellular localization of EGFP-Core fusion proteins into HepG2 cells. Three recombinant plasmids of pEGFP-Core with single, double and triple NLS of HBV core (EGFP-Core 1C, 2C and 3C ) and two recombinant plasmids with single and triple NLS of SV-40 (EGFP-Core 1 and 3 SV-40) were used in this work. After transient transfected into HepG2 cells and treated with Bayer 41-4109, the intracellular localization of expressed fusion proteins from all plasmid constructions were determined and quantified under confocal laser microscope. Results shown that Bayer 41-4109 treatment in HepG2 cells inhibited the nuclear localization of EGFP-Core with single of triple HBV core NLS. As well as the constructions of expressed fusion protein with single and triple SV-40 NLS (EGFP-Core 1 and 3 SV-40 NLS) showed decreasing the nuclear localization after treated with Bayer 41-4109, even not as strong as EGFP-Core 1C and 3C NLS. Bayer 41-4109 has been identified as a potent inhibitors of HBV replication which has multiple effects on HBV capsid assembly. It may inhibit virus replication by inducing assembly inappropriately and by misdirecting assembly decreasing the stability of normal capsids. Keywords: HBV capsid, Bayer 41-4109, EGFP-Core fusion protein, HepG2 cellhttps://jurnal.ugm.ac.id/ijbiotech/article/view/7775
spellingShingle Aris Haryanto
Nastiti Wijayanti
Michael Kann
Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins
Indonesian Journal of Biotechnology
title Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins
title_full Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins
title_fullStr Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins
title_full_unstemmed Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins
title_short Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins
title_sort effect of the hbv capsid assembly inhibitor bayer 41 4109 on the intracellular localization of egfp core fusion proteins
url https://jurnal.ugm.ac.id/ijbiotech/article/view/7775
work_keys_str_mv AT arisharyanto effectofthehbvcapsidassemblyinhibitorbayer414109ontheintracellularlocalizationofegfpcorefusionproteins
AT nastitiwijayanti effectofthehbvcapsidassemblyinhibitorbayer414109ontheintracellularlocalizationofegfpcorefusionproteins
AT michaelkann effectofthehbvcapsidassemblyinhibitorbayer414109ontheintracellularlocalizationofegfpcorefusionproteins